Current clinical data already support bile acid-based strategies in metabolic disease and neuroprotection, while novel agents targeting FXR, TGR5, and FGF19 signaling are emerging as promising tools for restoring disrupted gut–brain communication. Here, FGF19 is linked to Other metabolic disease.